Understanding The Psychedelic Medicine Industry: Q&A with Kevin O'Leary and JR Rahn

Moderated by Jeff Siegel of Green Chip Stocks, investor Kevin O' Leary and Co-founder & Co-CEO of MindMed JR Rahn hosted a live Q&A on 4/22/20 to answer questions submitted via email, Twitter, and during the webinar.

All rights reserved by MindMed.

Webcast Disclaimer
This webcast of Mind Medicine (MindMed) Inc. on April 22, 2020 contains "forward-looking information", which may include, but is not limited to, statements with respect to anticipated business plans or strategies of MindMed, the anticipated date of completion of micro-dosing studies, the timing of any drug trials, the success of its clinical trials, the ability to enter into acquisitions or collaborations to enhance its drug development platform, the success of any such acquisitions or collaborations and the ability to use the information relating to, or obtain patents or other intellectual property protection on, data and clinical trials generated directly by MindMed or through such acquisitions or collaborations, and the success or stage of development of discoveries or medicines. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MindMed to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in MindMed’s management’s discussion and analysis for the period from May 30, 2019, date of incorporation, to December 31, 2019 (“MD&A”), dated March 30, 2020, which is available on MindMed’s website and the company’s profile at www.sedar.com. Forward-looking statements contained herein are made as of the date of this webcast and MindMed disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management's estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the listener is cautioned not to place undue reliance on forward-looking statements.

Видео Understanding The Psychedelic Medicine Industry: Q&A with Kevin O'Leary and JR Rahn канала MindMed